Advances in the management of pediatric genitourinary rhabdomyosarcoma

Area of Science:

• Pediatric Oncology
• Radiation Oncology
• Medical Oncology

Background:

• Genitourinary rhabdomyosarcoma (RMS) management has evolved with improved outcomes for low- and intermediate-risk cases.
• Clinical trials aimed to reduce toxicity from surgery, radiotherapy, and chemotherapy in pediatric RMS.
• Historical risk stratification needs refinement based on recent trial outcomes.

Purpose of the Study:

• To review recent clinical trial results for genitourinary RMS.
• To discuss the implications for managing pediatric genitourinary RMS.
• To highlight complexities in optimizing treatment strategies.

Main Methods:

• Focus on results from recent rhabdomyosarcoma clinical trials.
• Analysis of treatment strategies including surgery, radiotherapy, and chemotherapy.
• Examination of differing international perspectives on risk-benefit balance.

Main Results:

• Trial results for reducing toxicity are mixed, indicating a need for refined risk stratification.
• Radiotherapy is standard for local control, with potential for toxicity reduction.
• Decreasing chemotherapy intensity requires careful consideration for most patients.
• International differences exist regarding toxicity versus survival trade-offs.

Conclusions:

• Optimal management of genitourinary RMS requires addressing unanticipated complexities.
• Future trials must carefully consider refining risk stratification and treatment intensity.
• Balancing toxicity reduction with efficacy remains a key challenge in pediatric RMS treatment.